NOVO — Februar 2025
-
Fra investor presentation i dag https://www.novonordisk.com/investors/financial-results.html
-
Novo Nordisk expects growth to slow this year as it faces "intensifying competition and continued pricing pressure" on its key obesity and diabetes franchises, along with ongoing supply challenges.
Despite this, the company projected Wednesday that 2025 sales will rise between 16% and 24% on a constant exchange rate (CER) basis – although that's pared back from the 26% growth achieved in 2024, when sales reached DKK 290 billion ($40.4 billion). https://firstwordpharma.com/story/5932839
-
Torsdagens aviser med Novo Nordisk, Vestas og Pandora https://proinvestor.com/investornyt/1274557/torsdagens-aviser-med-novo-nordisk-vestas-og-pandora
-
Her er lidt tanker om nye Cagrisema data https://proinvestor.com/boards/124611/
-
Novo er i færd med at skrue op for antallet af startdoser med Wegovy i USA https://proinvestor.com/investornyt/1274612/novo-er-i-faerd-med-at-skrue-op-for-antallet-af-startdoser-med-wegovy-i-usa
-
Novos topchef sælger aktier
i dag kl. 10:37 ∙ MarketWireNovo Nordisks topchef Lars Fruergaard Jørgensen har fået tildelt aktier for et pænt tocifret millionbeløb som led i et langsigtet incitamentsprogram, og har solgt en god bid igen.
Det fremgår af en indberetning til børsen om transaktioner den 5. februar efter offentliggørelsen af Novos årsregnskab.
I alt fik Lars Fruergaard Jørgensen onsdag fået overført 98.702 Novo-aktier som led i det langsigtede incitamentsprogram.
-
Og han solgte efterfølgende 34.999 Novo-aktier for et beløb i underkanten af 21,7 mio. kr.
I forvejen ejede Lars Fruergaard Jørgensen ved indgangen til 2025 i alt 590.550 Novo-aktier til en samlet værdi af 368,6 mio. kr.
.\˙ MarketWire
-
Novo-rival stiger oven på regnskabstal - indtjening er bedre end ventet https://proinvestor.com/investornyt/1274705/novo-rival-stiger-oven-pa-regnskabstal-indtjening-er-bedre-end-ventet
-
Kort videokommentar....Regnskaber: Novo Nordisk, Vestas, DSV, Mærsk, GN, Bavarian https://proinvestor.com/boards/124623
-
Netop lahn1.

-
Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors https://ml-eu.globenewswire.com/Resource/Download/899ac35c-8688-411e-818f-4f15dcc281fe
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind